Salem Investment Counselors’s Recursion Pharmaceuticals RXRX Stock Holding History

Salem Investment Counselors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.78K	Hold	2,120	–	–	﹤0.01%	947
2026 Q1	$6.51K	Buy	+2,120	New	+$8.19K	﹤0.01%	944
2025 Q4	–	Sell	-2,020	Closed	-$9.86K	–	985
2025 Q3	$9.86K	Hold	2,020	–	–	﹤0.01%	883
2025 Q2	$10.2K	Buy	2,020 +20	+1%	+$98	﹤0.01%	853
2025 Q1	$10.6K	Hold	2,000	–	–	﹤0.01%	833
2024 Q4	$13.5K	Hold	2,000	–	–	﹤0.01%	789
2024 Q3	$13.2K	Hold	2,000	–	–	﹤0.01%	807
2024 Q2	$15K	Hold	2,000	–	–	﹤0.01%	774
2024 Q1	$19.9K	Hold	2,000	–	–	﹤0.01%	710
2023 Q4	$19.7K	Buy	+2,000	New	+$14.3K	﹤0.01%	697

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Carroll Investors Mt Pleasant, South Carolina $234M AUM 59.79% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Allen Operations New York $722M AUM 20.02% 1-Year Est. Return

Salem Investment Counselors's RXRX Position: Q2 2026 in Review

Salem Investment Counselors held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 2,120 shares worth $7.78K. The position accounts for ﹤0.01% of the portfolio, ranked #947.

Salem Investment Counselors first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $19.9K in Q1 2024. 137 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Salem Investment Counselors held 2,120 shares of Recursion Pharmaceuticals worth $7.78K as of Q2 2026.
Salem Investment Counselors left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #947 holding.
Salem Investment Counselors first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Salem Investment Counselors's Recursion Pharmaceuticals position peaked at $19.9K in Q1 2024.
137 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.